mFOLFIRINOX

First-line mFOLFIRINOX for GI high grade neuroendocrine neoplasms, summarized by Erman Akkus

Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X:

“First-line mFOLFIRINOX for GI high-grade neuroendocrine neoplasms?

  • ORR: 77% (complete response: 3%; partial response: 74%)
  • mPFS: 12 months
  • mOS: 20.6 months

Retrospective, n=35.

Prospective clinical trials are needed, may be considered in patients with high tumor burden and who can tolerate.”

First-line mFOLFIRINOX for GI high grade neuroendocrine neoplasms, summarized by Erman AkkusFirst-line mFOLFIRINOX for GI high grade neuroendocrine neoplasms, summarized by Erman Akkus

First-line mFOLFIRINOX for GI high grade neuroendocrine neoplasms, summarized by Erman Akkus

 

Read further.
Source: Erman Akkus/X

Ankara University cancer Erman Akkus First-line mFOLFIRINOX high grade neuroendocrine neoplasms high tumor burden mFOLFIRINOX OncoDaily Oncology Prospective clinical trials